Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | SERENA-1 Parts K/L: camizestrant and ribociclib in ER+/HER2- breast cancer

Richard Baird • 12 Dec 2024
SABCS 2024
Breast Cancer Camizestrant Ribociclib
SERENA-1

Richard Baird, MD, PhD, University of Cambridge, Cambridge, UK, discusses findings from Parts K and L of the Phase I SERENA-1 trial (NCT03616587), evaluating camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), with ribociclib in ER+/HER2- advanced breast cancer. Initial efficacy was observed and the combination was well-tolerated, aligning with known safety profiles of each drug. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Radiation response as a biomarker for adjuvant breast cancer therapy
1:56
Radiation response as a biomarker for adjuvant breast cancer therapy
Corey Speers • 1 Jun 2026
Expanding the clinical use of multimodal AI in breast cancer care
1:38
Expanding the clinical use of multimodal AI in breast cancer care
Corey Speers • 1 Jun 2026
MMAI model validation for chemotherapy benefit prediction in breast cancer
1:58
MMAI model validation for chemotherapy benefit prediction in breast cancer
Corey Speers • 1 Jun 2026
GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: a real-world analysis
1:33
GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: a real-world analysis
Zunairah Shah • 30 May 2026
The content of VJOncology is intended for healthcare professionals